StreetAlpha
13F holdings · Q3 2026

Squadron Capital Management

Oak Brook, IL · files as Squadron Capital Management LLC
Know the moment Squadron Capital Management filesYou follow Squadron Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2050709

Squadron Capital Management reported 35 stocks worth $337M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (11.8%), CCCC (9.2%) and COGT (8.7%). Compared with Q2 2026, the fund opened new positions in SLN, ORIC and PHVS, added to CCCC, COGT and ZNTL, trimmed KOD, RLAY and RLMD and sold out of MAZE, ELVN and IFRX.

Latest filing: what Squadron Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
17 new9 added6 trimmed16 sold outBought about $147M · sold about $81.4M
New 17
See all 17 →
Added 9
See all 9 →
Trimmed 6
See all 6 →
Sold out 16
See all 16 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$337M+15.5% vs last quarter · $398M including options
Stocks held3517 new · 16 sold out
Top 5 weight42.0%fairly concentrated
Turnover68%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
KOD
Kodiak Sciences Inc
$39.8M11.8%420K−80K (−16%)4 of 4
2
CCCC
C4 Therapeutics Inc
$31M9.2%9.3M+2.1M (+29%)3 of 4
3
COGT
Cogent Biosciences Inc
$29.3M8.7%915K+50K (+6%)4 of 4
4
SLN
Silence Therapeutics PLC
$22.8M6.8%2.1MNew position1 of 4
5
ZNTL
Zentalis Pharmaceuticals Inc
$18.9M5.6%6.8M+3.1M (+85%)3 of 4
6
EWTX
Edgewise Therapeutics Inc
$17.3M5.1%425K+135K (+47%)4 of 4
7
RLAY
Relay Therapeutics Inc
$14.2M4.2%785K−185K (−19%)3 of 4
8
ORIC
Oric Pharmaceuticals Inc
$13.5M4.0%1MNew position1 of 4
9
RLMD
Relmada Therapeutics Inc
$13.2M3.9%3.5M−3.9M (−52%)4 of 4
10
DFTX
Definium Therapeutics Inc
$12.9M3.8%340K+255K (+300%)2 of 4
🔒 25 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
MAZE
Maze Therapeutics Inc
$10M335K
ELVN
Enliven Therapeutics Inc
$8.1M160K
FORTE BIOSCIENCES INC
$4.8M225K
IFRX
Inflarx N V
$4.5M2M
PMN
Promis Neurosciences Inc
$4.3M325K

🔒 Free account: see all 16.

Options

valued at the underlying shares
StockTypeValueSharesChange
KOD
Kodiak Sciences Inc
Call$25.6M270K+270,000
IRON
Disc Medicine Inc
Call$8.8M135K+104,500
COGT
Cogent Biosciences Inc
Call$8.5M265K+265,000
RZLT
Rezolute Inc
Call$5.5M1.3M+423,500
AVBP
Arrivent Biopharma Inc
Call$4.3M143K−40,500

🔒 Free account: see all 10.

Reported value

last 4 quarters
$224MQ4 '25
$250MQ1 '26
$292MQ2 '26
$337MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Squadron Capital Management 13F FAQ

What does Squadron Capital Management own?

Squadron Capital Management reported 35 stocks worth $337M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (11.8%), CCCC (9.2%) and COGT (8.7%). The table above lists every position in the filing (the top 10 without an account).

What did Squadron Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 17 new positions, 9 added to, 6 trimmed and 16 sold out. New positions include SLN, ORIC and PHVS. It sold all of MAZE, ELVN and IFRX.

When will Squadron Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Squadron Capital Management's portfolio worth?

The Q3 2026 filing reports $337M in US stocks ($398M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.